Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients

The purpose of this study was to conduct a retrospective analysis of serum phosphate level variability in patients new to hemodialysis (HD) and to identify patient characteristics associated with this variability. The medical records of 47,742 incident HD patients attending US outpatient dialysis ce...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nephrology and renovascular disease 2014-01, Vol.7 (default), p.261-269
Main Authors: Farrand, Kimberly F, Copley, J Brian, Heise, Jamie, Fridman, Moshe, Keith, Michael S, Poole, Lynne
Format: Article
Language:English
Subjects:
Bone diseases
Care and treatment
Diabetes
Diagnosis
Diseases
Hemodialysis
Hemodialysis patients
Kidney diseases
Malnutrition
Measurement
Metabolism
Mortality
Original Research
Patients
Peritoneal dialysis
Phosphates
Phosphorus
Phosphorus imbalance
Physiological aspects
Prognosis
Risk factors
Serum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to conduct a retrospective analysis of serum phosphate level variability in patients new to hemodialysis (HD) and to identify patient characteristics associated with this variability. The medical records of 47,742 incident HD patients attending US outpatient dialysis centers between January 1, 2006 and March 31, 2009 were analyzed. Monthly mean serum phosphate levels determined over a 6-month evaluation period (months 4-9 after HD initiation) were assigned to one of three strata: low (5.5 mg/dL]). Patients were classified into one of six serum phosphate variability groups based on variability among monthly mean phosphate levels over the 6-month evaluation period: consistently target; consistently high; high-to-target; high-to-low; target-to-low; or consistently low. Only 15% of patients (consistently target group) maintained monthly mean serum phosphate levels within the target range throughout the 6-month evaluation period. Age, Charlson comorbidity index, serum phosphate, and intact parathyroid hormone levels prior to HD initiation were strongly associated (P
ISSN:1178-7058
1178-7058
DOI:10.2147/IJNRD.S58037